Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode

Publisher Website
Google Scholar
Abstract
As many as 45% of patients with major depressive episode also meet DSM-IV criteria for bipolar II (BP II) disorder. Although some clinicians advocate using a mood stabilizer in treating BP II depression, antidepressant monotherapy has been less well studied in this disorder. As part of a prospective, placebo-controlled, relapse-prevention study in 839 patients, the efficacy and safety of short- and long-term fluoxetine treatment in patients with BP II major depression compared with patients with unipolar (UP) major depression was retrospectively examined. Eighty-nine BP II patients (mean age, 41 +/- 11 years) were compared with 89 age- and gender-matched UP patients and with 661 unmatched UP patients (mean age, 39 +/- 11 years). All received short-term fluoxetine therapy at 20 mg daily for up to 12 weeks. Complete remission was defined as a final Hamilton Rating Scale for Depression score

This publication has 17 references indexed in Scilit: